AH1 is an immunodominant antigen derived from the gp70 product of an endogenous MuLV. AH1 behaves as the CTL-immunodominant epitope of CT26 colon carcinoma.
References:
[1]. M Toda, et al. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther. 1999 Feb 10;10(3):385-93.
[2]. Antonio Rosato, et al. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. Cancer Res. 2003 May 1;63(9):2158-63.
















